ASH 2020 | Bispecific antibody therapies for myeloma at ASH 2020
Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ, discusses exciting new research into bispecific antibody therapies for the treatment of multiple myeloma, as presented at ASH 2020. While extensive research has focused on BCMA-targeting agents, the newly identified targets GPRC5C and FcRH5 are now being investigated. FcRH5 in particular has shown impressive response rates in patients with an extensive history of prior treatment. Novel bispecific antibody therapies have an encouraging initial safety profile, however, further research in larger patient cohorts is needed to evaluate the efficacy of treatment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Rafael Fonseca, MD, has done consultancy work with Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Karyopharm, Merck, Juno, Kite, Aduro, OncoTracker, Oncopeptides, GSK and AbbVie; and has participated in scientific advisory boards for Adaptive Biotechnologies, Caris Life Sciences and OncoTracker.
